Hemolytic uremic syndrome in prostatic carcinoma.
BACKGROUND
Disseminated intravascular coagulation is a well-known complication of adenocarcinoma of the prostate, while hemolytic uremic syndrome (HUS) is not.


METHODS
We describe the unusual case of a 61-year-old patient with adenocarcinoma of the prostate. Prior to any systemic therapy he developed hemolytic uremic syndrome (HUS) necessitating dialysis. Renal function has fully recovered and he is alive and well 7 years later.


CONCLUSIONS
HUS is a rare complication of adenocarcinoma of the prostate and has a far better prognosis than chemotherapy-associated HUS.
Müller
N J
NJ
Department of Internal Medicine, University Hospital, Zurich, Switzerland.
Pestalozzi
B C
BC
D000230:Adenocarcinoma / Q000150:complications*; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology* / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000150:complications*; D006435:Renal Dialysis